A detailed history of China Universal Asset Management Co., Ltd. transactions in Xencor Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,893 shares of XNCR stock, worth $286,978. This represents 0.03% of its overall portfolio holdings.

Number of Shares
11,893
Previous 7,243 64.2%
Holding current value
$286,978
Previous $137,000 74.45%
% of portfolio
0.03%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$15.7 - $21.65 $73,005 - $100,672
4,650 Added 64.2%
11,893 $239,000
Q2 2024

Jul 19, 2024

SELL
$18.21 - $24.5 $82,163 - $110,544
-4,512 Reduced 38.38%
7,243 $137,000
Q1 2024

Apr 29, 2024

BUY
$18.65 - $26.52 $87,916 - $125,015
4,714 Added 66.95%
11,755 $260,000
Q4 2023

May 21, 2024

SELL
$16.53 - $21.42 $77,922 - $100,973
-4,714 Reduced 40.1%
7,041 $149,000
Q4 2023

Jan 23, 2024

BUY
$16.53 - $21.42 $90,799 - $117,660
5,493 Added 354.84%
7,041 $149,000
Q3 2023

May 21, 2024

BUY
$20.08 - $25.39 $15,180 - $19,194
756 Added 95.45%
1,548 $31,000
Q3 2023

Oct 30, 2023

BUY
$20.08 - $25.39 $15,180 - $19,194
756 Added 95.45%
1,548 $31,000
Q2 2023

May 21, 2024

SELL
$24.77 - $29.9 $544 - $657
-22 Reduced 2.7%
792 $19,000
Q2 2023

Jul 27, 2023

SELL
$24.77 - $29.9 $544 - $657
-22 Reduced 2.7%
792 $20,000
Q1 2023

May 21, 2024

BUY
$25.95 - $36.95 $5,319 - $7,574
205 Added 33.66%
814 $22,000
Q1 2023

Apr 27, 2023

BUY
$25.95 - $36.95 $5,319 - $7,574
205 Added 33.66%
814 $23,000
Q4 2022

May 21, 2024

SELL
$24.79 - $30.86 $276,309 - $343,965
-11,146 Reduced 94.82%
609 $15,000
Q4 2022

Jan 31, 2023

BUY
$24.79 - $30.86 $1,239 - $1,543
50 Added 8.94%
609 $16,000
Q3 2022

Oct 21, 2022

BUY
$24.62 - $32.44 $13,762 - $18,133
559 New
559 $15,000

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.44B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.